Familial hypercholesterolemia (FH) is an inherited disorder. The level of low-density
lipoprotein cholesterol (LDL-C) in patients with homozygous FH can be twice as high as that …

Dyslipidemias have emerged as prevalent disorders among patients, posing significant risks
for the development and progression of cardiovascular diseases. These conditions are …

In 2023 there are still even 75% of patients over the target of low-density lipoprotein
cholesterol (LDL-C), and hypercholesterolemia is the most common and the worst monitored …

Abstract Purpose of Review Globally, the prevalence of metabolic disorders is rising.
Elevated low-density lipoprotein (LDL) cholesterol is a hallmark of familial …

Dyslipidemia in patients with type 2 diabetes (DMT2) is one of the worst controlled
worldwide, with only about 1/4 of patients being on the low-density lipoprotein cholesterol …

Cardiovascular diseases still constitute the most frequent cause of both hospitalization and
death worldwide. The classic modifiable risk factors for cardiovascular disease are …

The reduction of circulating low-density lipoprotein-cholesterol (LDL-C) is a primary target in
cardiovascular risk reduction due to its well-established benefits in terms of decreased …

Leczenie dyslipidemii w Polsce — interdyscyplinarne stanowisko grupy ekspertów wsparte
przez Sekcję Farmakoterapii Sercowo-Naczyniowej Polskiego Towarzystwa …

Familial hypercholesterolemia (FH) is an underdiagnosed disease that contributes to a
significant number of cardiovascular incidents through high serum Low-Density Lipoprotein …

[1] S. Surma, M. Romanczyk, KJ Filipiak, Evinacumab-a new drug in the treatment of
homozygous familial hypercholesterolaemia, Integr. Canc. Sci. Therapeut.(2021), https://doi …